Guest Editors play a significant role in a special issue. They maintain the quality of published research and enhance the special issue’s impact. If you would like to be a Guest Editor or recommend a colleague as a Guest Editor of this special issue, please Click here to fulfill the Guest Editor application.
One of the most difficult challenges faced in buying in the pharmaceuticals market is whether to buy prescribed pharmaceuticals products or the same molecule-based cheap pharmaceuticals products. The question to the patients：What is the real market price of the medicine? The question to the retailers who buys from stockiest, what is the real price of the medicine and how much bonus is demanded? The question to the stockiest, who buys medicine in bulk quantity from pharmaceuticals manufacturers or suppliers, how much incentive and/or scheme, be demanded in the product? And ultimately, to the manufacturers, how much package should be established in order to get expected rate of return on the pharmaceuticals products? And next to the society, what is its value to the society, to the individual patient? If cost-effectiveness were the final arbiter of pricing decisions, most pharmaceutical prices could justifiably be much higher than they are. Simply noted, it is important to establish prices for pharmaceuticals products that will produce an appropriate return on the research investment and maximize patient access. If the price is too high and the patient cannot afford the medicine, the question for reason for existence is always there.